Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTX 110

Drug Profile

CTX 110

Alternative Names: Anti-CD19+ CAR-T cells - CRISPR Therapeutics; CTX 101 - CRISPR Therapeutics; CTX110

Latest Information Update: 19 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CRISPR Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B-cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 29 Jul 2019 Phase-I/II clinical trials in B-cell lymphoma (Second-line therapy or greater) in USA (IV) (NCT04035434)
  • 29 Jul 2019 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT04035434)
  • 29 Apr 2019 The Health Canada approves a CTA application for CTX 110 in Haematological malignancies, prior to April 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top